drugs used include lithium and valproic acid. In addition, antiepileptic drugs, such as carbamazepine, sodium valproate (off-licence) and lamotrogine, may be helpful.
The use of these drugs is mentioned in the British Association of Psychopharmacology guidelines (Goodwin, 2003) . Issues can arise when sodium valproate is prescribed off-licence. Firstly, patient consent must be obtained and this is often difficult if the patients themselves do not feel ill. Secondly, the doses prescribed are based on those prescribed in epilepsy. The British National Formulary does not indicate a dose for sodium valproate in bipolar affective disorder (Joint Formulary Committee, 2010) . The doses may not be effective and often, higher doses are needed in bipolar affective disorder, which has lead to physicians abandoning its use.
Brain chemistry
The brain chemistry of patients with BPAD has been studied, and several changes in neurotransmitter levels have been observed. During mania, raised levels of dopamine, glutamate, noradrenalin and serotonin have been recorded (Voelker, 2000) , along with reduced levels of gamma-aminobuytric acid (GABA) (Petty, 1993) . During depression, reduced levels of serotonin, noradrenaline, dopamine, GABA and myo-inositol have been recorded, as well as raised levels of glutamate (Frye et al, 2007) .
The exact mechanism of action of mood stabilizers is poorly understood.
Valproic acid reduces abnormal electrical activity in the brain via inhibition of sodium channels, and may also increase GABA activity through the inhibition of the two enzymes responsible for the inactivation of GABA. It is also possible that valproic acid may also enhance the post-synaptic action of GABA (Karch, 2008) .
The mode of action of lithium is still not fully understood. In mania, one theory is that the patient experiences excessive catecholamine stimulation. In bipolar disorder, the patient is affected by swings between excessive catecholamine stimulation of mania and the diminished catecholamine stimulation of depression. Lithium is also thought to reduce dopamine levels in the central nervous system (Scott and McGrath, 2009 B ipolar affective disorder (BPAD) is an illness that causes two distinct mood disturbances (poles), mania and depression. It has been a recognized illness since Aretaeus of Cappadocia, a Greek physician, first observed that melancholia and mania were linked in some people, and that these conditions could switch or be present as a mixture of symptoms (Sie, 2009) .
The World Health Organization estimates BPAD to be the seventh leading cause of 'non-fatal burden of disease '(Ayuso-Mateos, 2000) . In the UK, treating BPAD costs the NHS an estimated £200 million per year (Das, 2002) . Those with BPAD have been shown to have a lower physical and mental quality of life compared with the general population (Gutierrez-Rojas, 2008) .
BPAD is classified into two types: bipolar I disorder, in which episodes of mood disturbance are predominantly manic with occasional depressive episodes; and bipolar II disorder, in which the episodes fluctuate between hypomania (a mood disturbance similar to mania but less severe) and depression (Sie, 2009) .
The drugs that specifically target this condition are referred to as mood stabilizers, or antimanic drugs. 'Mood stabilizer' is a poorly defined term used to describe medicines that can both prevent and treat acute (hypo) manic and depressive BPAD episodes. The ideal mood stabilizer would prevent relapse of mania and depression; however, the current pharmacological treatments tend to be more effective at treating one or the other. The main 
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Monitoring
Start at 400 mg once daily (200 mg in the elderly). Measure plasma levels after 7 days, then every 7 days until the required level is reached (0.4-0.8 mmol/l). Once stable, check every 3 months. Check urea and electrolytes, and thyroid function tests every 6 months
Stopping
Slowly reduce over at least 1 month From: Taylor et al (2007) of mania, in the prophylaxis of bipolar disorder (manicdepressive disorder), and in the prophylaxis of recurrent depression (Table 1 ) (Joint Formulary Commitee, 2009 ). The decision to give prophylactic lithium must be based on careful consideration of the likelihood of recurrence in the individual patient, and the benefit weighed against the risks. In long-term use, lithium has been associated with thyroid disorders and mild cognitive and memory impairment (Joint Formulary Commitee, 2009) .
Lithium is usually prescribed once daily at night, with a starting dose of 400 mg/day and titrated up gradually according to patient's response and tolerability. Serum levels of lithium are generally taken five days after commencing treatment. Blood samples should be taken 12 hours post-dose, i.e. first thing in the morning. Serum levels of 0.4-0.8 mmol/l are required for maintenance therapy. Higher levels of 0.8-1.2 mmol/l may be required for acute therapy, but these are usually determined by each individual hospital's protocols. The acute toxic effects of lithium become more likely when serum levels exceed 1.5 mmol/l) (Joint Formulary Committee, 2010).
Side-effects
The side-effects of lithium include a fine tremor, sedation or lethargy, impaired coordination, gastric disturbances, polyuria (increased frequency of passing water), polydipsia,(feeling very thirsty), weight gain, oedema, and hypothyroidism (Joint Formulary Committee, 2010).
Toxicity
Signs of toxicity include nausea, vomiting, diarrhoea, drowsiness, ataxia, coarse tremor, myoclonic jerks, confusion, seizures, coma, and death.
Lithium plasma levels may be increased by: n Sodium or fluid depletion (e.g. from vomiting, diarrhoea or dehydration)
n Impaired renal function n Certain medicines (e.g. thiazide diuretics such as bendroflumethiazide, non-steroidal anti-inflammatory drug such as ibuprofen, or angiotensin-converting enzyme inhibitors such as lisinopril) n Change in brand or formulation of lithium.
Patients should be educated about the signs of toxicity, and reporting these immediately. A lithium treatment card, available from pharmacies, tells patients how to take lithium preparations, what to do if a dose is missed and what side-effects to expect. It also explains why regular blood tests are important and warns that some medicines and illnesses can change serum lithium concentration.
While there is no clear evidence of withdrawal or rebound psychosis, abrupt discontinuation of lithium increases the risk of relapse. If lithium is to be discontinued, the dose should be reduced gradually over a period of a few weeks, and patients should be warned of possible relapse (Joint Formulary Committee, 2010) .
Formulations
Lithium salts are available as tablets and liquid. Lithium carbonate is available in tablet formulation, and it is important that once patients are stabilized on a particular brand they are not interchanged with other brands, as bioavailability may vary. Lithium citrate is available in liquid formulation. It is available as an oral solution of 509 mg/5 ml (lithium + 5.4 mmol/5 ml), i.e. lithium carbonate 200 mg = lithium citrate 509 mg (Joint Formulary Committee, 2010) .
The liquid is more suitable for adults with swallowing difficulties and the elderly. It can be mixed in diluted squash and fruit juice prior to administration.
Blood tests
Patients on lithium are advised to have lithium blood levels measured every 3 months. In addition, thyroid function tests and urea and electrolytes (to check renal function) should be measured every six months once patients are stabilized on therapy ( Table 1) .
Valproate
Two valproic acid salts are available in the UK: semisodium valproate (Depakote, licensed for the treatment of acute mania) and sodium valproate (licensed for the treatment of epilepsy). Before semisodium valproate was licensed as a treatment for acute mania, sodium valproate was used quite extensively off-licence, both in the UK and in the USA. Indeed, many of the US research papers still quote its usage.
Semisodium valproate is a 1:1 molar combination of sodium valproate and valproic acid (Walker and Whittlesea, 2007) . Following administration, the valproate ion is released, and subsequently absorbed. The therapeutic differences between sodium valproate and semisodium valproate have not yet been established.
The mechanism of action in mania is unclear, but may be related to increased levels of gamma aminobutyric acid (GABA). The antimanic effects of valproate are seen within three days, but full benefit of treatment may not be apparent for up to three weeks. Dosage should be rapidly titrated up between 1000 mg and 2000 mg/day. Routine plasma level measurements are not necessary.
Side-effects
Side-effects include gastric irritation, tremor, ataxia, sedation, hair loss, increased appetite, and weight gain. Liver function tests should be performed prior to treatment, and then annually once treatment is established (Joint Formulary Committee, 2010) .
Interactions with other drugs
Valproate is highly protein-bound (up to 94%) (Taylor et al, 2007) . Other drugs that are highly protein-bound can displace valproate from albumin and precipitate toxicity (e.g. aspirin) (Goulden et al,1987) . Other less strongly bound drugs can be displaced by valproate, leading to higher free levels and increased therapeutic effect or toxicity (e.g. warfarin).
Valproate is hepatically metabolized: drugs that inhibit cytochrome P (CYP) enzymes can increase valproate levels (e.g. erythromycin, fluoxetine and cimetidine). Valproate can increase the plasma levels of some drugs, possibly by inhibition/competitive inhibition of their metabolism (Taylor et al, 2007) . Examples include clomipramine (Fehr et al, 2000) , lamotrogine and phenobarbita (Taylor et al, 2007) .
Use of valproate in women of childbearing age
Valproate is an established teratogen. The risk of fetal malformation is 7.2% (National Institute for Health and Clinical Excellence (NICE), 2004), mostly due to neural tube defects. The National Institute for Health and Clinical Excellence (NICE) recommends that alternative anticonvulsants be preferred in women with epilepsy (2004), and valproate not be routinely used to treat bipolar illness in women of childbearing age (2006).
Carbamazepine
Carbamazepine is primarily used as an anticonvulsant in the treatment of grand mal and focal seizures. It is also used in the management of trigeminal neuralgia and, in the UK, it is licensed for the prophylaxis of bipolar illness in patients who do not respond to lithium (Joint Formulary Committee, 2010) . NICE does not recommend carbamazepine as a firstline treatment for mania (2006) .
Carbamazepine may also be useful to augment antidepressants or other mood stabilizers in refractory unipolar depression (Taylor et al, 2007) , although its enzyme-inducing properties complicate treatment. NICE considers carbamazepine to be a thirdline prophylactic agent (2006) .
It is perceived wisdom that carbamazepine is more effective than lithium in rapid-cycling illness (four or more episodes/year). Although some evidence supports this view (Goodwin, 2003) , negative studies have been published. Pharmacology prophylaxis of bipolar disorder unresponsive to lithium, the initial regimen should be 400 mg daily, in divided doses, which should be increased until symptoms are controlled. The usual range is 400-600 mg daily; the maximum dose is 1.6 g daily (Joint Formulary Committee, 2010) .
Plasma levels
Plasma levels are usually an indicator for compliance. They are not always useful, because carbamazepine can induce the metabolism of other drugs, in addition to its own (Walker and Whittlesea, 2007) . The initial plasma half-life of approximately 30 hours is reduced to about 12 hours with chronic dosing.
Different preparations may vary in bioavailability; to avoid reduced effect or excessive side-effects, it may be prudent to avoid changing the formulation.
Adverse effects
The main problems encountered with carbamazepine therapy are dizziness, ataxia and nausea (Taylor et al, 2007) . This can be largely avoided by starting with a low dose, and increasing it slowly. These side-effects may also be reduced by altering the timing of medication, and through the use of modified-release tablets.
Carbamazepine can induce a low white blood cell count (WBC). Patients and their carers should be told how to recognize signs of blood, liver or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, sore throat, rash, mouth ulcers, brusing, or bleeding develop.
Most side-effects of carbamazepine are dose-related (peak plasma level-related), and increase in frequency and severity when plasma level is > 1 mg/l (this varies from patient to patient) (Taylor et al, 2007) .
Interactions with other drugs
Carbamazepine is a potent inducer of CYP450 enzymes, and is metabolized by CYP3A4. The plasma levels of most antidepressants, most antipsychotics, benzodiazepines, some cholinesterase inhibitors, methadone, thyroxine, theophylline, oestrogens, and other steroids may be reduced by carbamazepine, resulting in treatment failure. Drugs that inhibit CYP3A4 will increase carbamazepine plasma levels and may precipitate toxicity. Examples include cimetidine, diltiazem, verapramil, erythromycin, and serotoninspecific reuptake inhibitors (SSRIs) (Taylor et al, 2007) .
There are many complex interactions with other anticonvulsant drugs. The latest edition of the British National Formulary should be checked before prescribing anticonvulsant polypharmacy (Joint Formulary Committee, 2010) .
Lamatrogine
Although lamatrogine is only licensed for epilepsy, it is mentioned in NICE guidance to be used when 'a trial of prophylactic agents fail' , especially if the patient has bipolar II disorder (NICE, 2006) .Currently, much of the evidence to support the use of lamotrogine is for preventing depressive, not manic episodes.
Dosage
Lamatrogine should be titrated gradually, to minimize the risk of skin rashes, such as Steven-Johnson syndrome. Most rashes occur in the first 8 weeks. A rash is sometimes associated with hypersensitivity syndrome, and is more common in patients with history of allergy, or rashes from other antiepiletic drugs. The committee of safety of medicines has advised that factors associated with increased risk of serious skin reactions include concomitant use of valproate. Therapeutic doses in BPAD are similar to those used in epilepsy.
Dosage is initially 25 mg once daily for 14 days, increased to 50 mg once daily for a further 14 days, then increased by 50-100 mg daily maximum every 7-14 days. The usual maintenance dose is 100-200 mg, in divided doses. Dose titration should be repeated if restarting after an interval of more than 5 days (Joint Formulary Committee, 2010) .
Other drugs
Although antipsychotics such as olanzapine and aripiprazole are not strictly classified as mood stabilizers in patients whose manic episode has responded to olanzapine or aripiprazole treatment, both drugs are indicated for the prevention of recurrence in patients with bipolar disorder. In the case of ariprazole, this is restricted to bipolar I (NICE, 2006) , The doses to be used are the same as those used in the initial treatment of mania.
For aripiprazole, this is initially 15 mg daily. This can be increased to 30 mg daily, depending on response.
For olanzapine, the starting dose in mania is 15 mg daily. This is reduced to 10 mg daily if given in combination with other antiepileptic drugs.
Side-effects
As with all drugs, antipsychotics have a number of sideeffects. All antipsychotics can cause extrapyradimal sideeffects (Joint Formulary Committee, 2010). These include:
Lithium salts are used in the prophylaxis and treatment of mania, in the prophylaxis of bipolar disorder, and in the prophylaxis of recurrent depression.
n Parkinsonian symptoms n Dystonia (abnormal face movements) n Tardive dyskinesia (rhythmic, involuntary movements of the face and tongue and jaw). This usually develops after prolonged therapy. Both olanzapine and aripiprazole belong to a group of antipsychotics known as atypical antipsychotics, which have a reduced propensity to cause extrapyradimal side-effects.
Common side-effects in this group include drowsiness, weight gain, apathy, and agitation (Joint Formulary Committee, 2010) .
All patients on antipsychotics should be monitored for metabolic syndrome.
Metabolic syndrome
Metabolic syndrome is a combination of medical disorders that increases the risk of developing cardiovascular disease and diabetes. All patients who are administered an antipsychotic should have the following parameters measured: n Personal family history n Waist circumference n Blood pressure n Fasting or random blood glucose n Fasting lipid profile.
This should be done at the start of treatment, after four months, and then annually. Furthermore, it is now suggested that all patients on antipsychotics should have a baseline ECG performed to exclude any untoward abnormalities such as a prolonged QT interval (Dawda, 2009 ).
Conclusion
Bipolar affective disorder is a chronic, relapsingremitting disorder. Although there is no known cure, pharmacological treatment can substantially decrease the morbidity and mortality associated with the disorder.
Treatment aims include: maximizing the patient's level of personal and social functioning by ameliorating the severity of symptoms; reducing the frequency of recurrent instability in mood; and minimizing the adverse effects of treatment. Ultimately, the long-term aim is to prevent relapse and reduce the risk of suicide.
Mood stabilizers are a group of drugs used in mania and depression to control acute attacks and prevent their recurrence. Mood stabilizers include antiepileptics and some antipsychotics, which have a number of associated side-effects.
Therefore, careful consideration of the patient's age and history should be considered when making treatment choices.
